# A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension

> **NCT06438172** · PHASE3 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 249 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** HCP1803-3
- **DRUG:** RLD2001-1
- **DRUG:** HPP2003-3
- **DRUG:** HPP2002-1

## Key facts

- **NCT ID:** NCT06438172
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-25
- **Primary completion:** 2024-12-02
- **Final completion:** 2024-12-02
- **Target enrollment:** 249 (ACTUAL)
- **Last updated:** 2025-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06438172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06438172, "A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06438172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*